Bayer AG
XETRA:BAYN
Bayer AG
XETRA:BAYN
Price:
26.97 EUR
-1.39%
Market Closed
Updated:
Apr 24, 2024
Bayer AG
Cost of Revenue
Last
Value
3-Years CAGR
5-Years CAGR
|
Bayer AG
Cost of Revenue Peer Comparison
Comparables:
ATAI
MRK
93M1
DMP
PSG
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bayer AG
XETRA:BAYN
|
Cost of Revenue
-€19.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Cost of Revenue
-€8.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cost of Revenue
-€416.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cost of Revenue
-€9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
See Also
What is Bayer AG's Cost of Revenue?
Cost of Revenue
-19.7B
EUR
-19.7B
EUR
Based on the financial report for Dec 31, 2023, Bayer AG's Cost of Revenue amounts to -19.7B EUR.
What is Bayer AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
0%
0%
Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for Bayer AG have been -1% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
